ClinicalTrials.gg
RecruitingNCT06617416Updated Mar 12, 2025

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

A Phase 3 interventional study of Cadonilimab (AK104) and Sugemalimab in NSCLC (Non-small Cell Lung Cancer), sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung — 10 open to participants now, 13 under way, 2 of them phase 3. cadonilimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 15
560 · median 44
Started
2024
with 2 others
Phase 3
2 of 15
2 open now
Primary completion
2026-10
later than 9 of 12 live
Registered
13th of 15
by date
Lead sponsor
4 of 15
Akeso

Among the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 9 of the 12 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cadonilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must sign the written form (ICF) voluntarily.
  2. Age ≥18 years.
  3. or cytologically confirmed unresectable locally advanced (Stage III) NSCLC.
  4. Absence of known EGFR sensitive mutations and negative for ALK and ROS1 fusions.
  5. Concurrent or sequential chemoradiotherapy completed 1 to 42 days prior to the first dose.
  6. Chemotherapy regimens should be in accordance with current clinical guidelines.
  7. Consolidation chemotherapy is not allowed after radiotherapy.
  8. Total dose of radiotherapy is 60Gy±10% (54Gy-66Gy).
  9. No disease progression after concurrent or sequential chemoradiotherapy.
  10. performance status score of 0-1.
  11. Expected survival of over 3 months.
  12. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. The histopathology contains any component of small cell lung cancer.
  2. Currently participating in another interventional clinical study.
  3. Previously received immunotherapy, biotherapy, anti-angiogenic drugs, or small molecule targeted drugs.
  4. Patients with cardio-cerebrovascular or venous thromboembolic diseases.
  5. Prior active within the previous 3 years except for the locally curable cancers that have been apparently cured.
  6. Tumor invades important vessels or organs.
  7. Experienced acute exacerbation of or asthma within 4 weeks prior to the first dose.
  8. Presence of interstitial lung disease that requires treatment.
  9. Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1 ( version 5.0).
  10. Experienced severe infection within 4 weeks prior to the first dose.
  11. Underwent major surgery or experienced severe trauma within 4 weeks prior to the first dose.
  12. Any condition that required systemic treatment with (> 10 mg daily prednisone or equivalent) or other agents within 14 days prior to the first dose.
  13. Active diseases or history of autoimmune diseases that may relapse.
  14. Previous history of severe reactions to other monoclonal antibodies.
  15. Previous organ transplantation or hematopoietic stem cell transplantation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    AK104 group

    AK104 Q3W

    Drug: Cadonilimab (AK104)

  • Active comparator
    Sugemalimab group

    Sugemalimab 1200mg Q3W

    Drug: Sugemalimab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by INV

    PFS is defined as the time from randomization until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).

    Time frame: 3 years

Secondary outcomes

  1. OS

    Time from randomization to death

    Time frame: 5 years

  2. 6-month PFS rate assessed by INV

    PFS rate at 6 months

    Time frame: 3 years

  3. AEs

    Adverse events incidence and severity, clinically significant abnormal laboratory test results.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2026, 23 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 23 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Sep 27, 2024
StartActual
Nov 12, 2024
Primary completionEst.
Oct 28, 2026
CompletionEst.
Dec 30, 2028
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06617416
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Nov 12, 2024
Primary completion
Oct 28, 2026 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Mar 12, 2025

Study contacts

Ting Liu, MD
Contact
clinicaltrials@akesobio.com
+86-0760-89873925
Jinming Yu, MD
principal investigator · Shandong Cancer Hospital and Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion